Cargando…
Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy
Huntington’s Disease (HD) is a dominantly inherited neurodegenerative disease for which the major causes of mortality are neurodegeneration-associated aspiration pneumonia followed by cardiac failure. mTORC1 pathway perturbations are present in HD models and human tissues. Amelioration of mTORC1 def...
Autores principales: | St-Cyr, Sophie, Child, Daniel D., Giaime, Emilie, Smith, Alicia R., Pascua, Christine J., Hahm, Seung, Saiah, Eddine, Davidson, Beverly L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423655/ https://www.ncbi.nlm.nih.gov/pubmed/36037192 http://dx.doi.org/10.1371/journal.pone.0273710 |
Ejemplares similares
-
Discovery of NV-5138, the first selective Brain mTORC1 activator
por: Sengupta, Shomit, et al.
Publicado: (2019) -
Cardiac mTORC1 Dysregulation Impacts Stress Adaptation and Survival in Huntington’s Disease
por: Child, Daniel D., et al.
Publicado: (2018) -
Temporal Phenotypic Changes in Huntington’s Disease Models for Preclinical Studies
por: St-Cyr, Sophie, et al.
Publicado: (2022) -
A small molecule inhibitor of Rheb selectively targets mTORC1 signaling
por: Mahoney, Sarah J., et al.
Publicado: (2018) -
mTORC1 and mTORC2 in cancer and the tumor microenvironment
por: Kim, Laura C., et al.
Publicado: (2016)